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Abstract
H7N9 has caused fatal infections in humans. A safe and effective vaccine is the best way to
prevent large-scale outbreaks in the human population. Parainfluenza virus 5 (PIV5), an
avirulent paramyxovirus, is a promising vaccine vector. In this work, we generated a recom-
binant PIV5 expressing the HA gene of H7N9 (PIV5-H7) and tested its efficacy against in-
fection with influenza virus A/Anhui/1/2013 (H7N9) in mice and guinea pigs. PIV5-H7
protected the mice against lethal H7N9 challenge. Interestingly, the protection did not re-
quire antibody since PIV5-H7 protected JhD mice that do not produce antibody against le-
thal H7N9 challenge. Furthermore, transfer of anti-H7 serum did not protect mice against
H7N9 challenge. PIV5-H7 generated high HAI titers in guinea pigs, however it did not pro-
tect against H7N9 infection or transmission. Intriguingly, immunization of guinea pigs with
PIV5-H7 and PIV5 expressing NP of influenza A virus H5N1 (PIV5-NP) conferred protection
against H7N9 infection and transmission. Thus, we have obtained a H7N9 vaccine that pro-
tected both mice and guinea pigs against lethal H7N9 challenge and infection respectively.
Introduction
Influenza virus is a segmented, negative strand, RNA virus belonging to the Orthomyxoviridae
family [1]. Influenza viruses are classified into three families, types A, B, and C, with types A
and C infecting a variety of species, including humans and birds, and type B infecting primarily
humans. Only influenza A virus is associated with pandemics. Influenza A virus is classified by
its two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). There are
18 HA and 11 NA subtypes, differing by 30% in protein sequence similarity, which are used
to categorize influenza A virus into subtypes (e.g. H1N1, H3N2, H5N1, etc.) [2–4]. The first
wave of infection and fatality cases in humans by avian influenza A virus H7N9 were reported
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in April of 2013 with reported a mortality rate over 30% [5]. There is the urgent need for devel-
oping a H7N9 vaccine. Results from mice and humans show that H7 is poorly immunogenic in
producing anti-HA neutralizing antibodies [6, 7], a hallmark of influenza protection. Human
clinical trials using inactivated influenza virus containing H7 or virus-like particles containing
H7 and N9 have been disappointing: only 6% to16% of vaccinees developed immunity consid-
ered protective respectively, which is defined as a hemagglutination-inhibition (HAI) titer
higher than 40. While an adjuvant improved efficacy of the inactivated H7N9 vaccine, adverse
effects associated with adjuvants hinder use, especially in a mass immunization program [8, 9].
New vaccination strategies are needed for the prevention and control of H7N9 infection.
A viral vector-based vaccine provides a viable alternative. Parainfluenza virus 5 (PIV5) is a
promising viral vector for vaccine development. PIV5 is a non-segmented, negative strand,
RNA virus (NNSV). It is a member of the Rubulavirus genus of the family Paramyxoviridae,
which includes mumps virus (MuV), human parainfluenza virus type 2 (HPIV2) and type 4
(HPIV4) [10]. Several characteristics of PIV5 make it an attractive vaccine vector. First, PIV5 is
not known to cause any illness in humans. Vaccines containing live PIV5, a contributing factor
for causing kennel cough, have been used in dogs for over 30 years. Due to close interaction
with dogs, humans are likely exposed to this virus, as evident in our studies where we found
that about 30 percent of humans have neutralizing antibodies against PIV5 [11]; however, no
recorded illness in humans has been attributed to the virus. Second, PIV5 can be produced in
high titers in many cell lines, including Vero cells, which have been approved for vaccine pro-
duction [10]. Third, PIV5 can efficiently infect human cell lines and primary human cells [12].
Fourth, in our recent study, we have found that pre-existing immunity against PIV5 does not
negatively affect immunity generated by a PIV5-based vaccine [13]. Lastly, we have shown
PIV5 vaccination capable of inducing rapid protective immunity. In mice, a single-dose immu-
nization of PIV5 expressing the HA from H5N1 [14] or the G protein from rabies virus [11]
protected against a lethal influenza or rabies virus challenge, respectively. In addition, PIV5 ex-
pressing the NP protein of influenza virus provides broad protection against different subtypes
of influenza viruses in mice [15]. Together, these results demonstrate that PIV5 is an effective
vaccine vector. Importantly, intranasal administration of PIV5 is effective for eliciting robust
mucosal immune responses [16], and thus ideal for vaccinating against respiratory pathogens.
In this work, we have generated recombinant PIV5 expressing HA of H7N9 (PIV5-H7) and




A plasmid containing the codon-optimized HA gene from A/Anhui/1/13 (H7N9) was ordered
from GenScript. PIV5-H7, with the H7 gene inserted between SH and HN, was rescued using
the plasmid encoding the full-length PIV5 genome as described previously in Li et al [14]. Gen-
eration of PIV5-NP was previously described [15]. PIV5, PIV5-H7 and PIV5-NP stocks were
propagated in MDBK cells [17]. A/Anhui/1/2013 (H7N9), was provided via Richard Webby
(St. Jude Children’s Research Hospital, Memphis, TN) through the WHO Global Influenza
Surveillance and Response System (GISRS). A/Vietnam/1203/2004 (H5N1) was generously
provided by Richard Webby. Influenza viruses were grown in 9-day old embryonated hen eggs
and titrated on MDCK cells as previously described [14, 16]. All experiments using live H7N9
and H5N1 were conducted under ABSL3/BSL3+ conditions following protocols approved by
the Institutional Biosafety Committee and Institutional Animal Care and Use Committee at
the University of Georgia. Work with A/Vietnam/1203/04 (H5N1) was conducted following
PIV5-Based H7N9 Vaccine
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guidelines for use of Select Agents approved by the Centers for Disease Control and Preven-
tion/Division of Select Agents and Toxins and the Animal and Plant Health Inspection Ser-
vices/Agricultural Select Agent Program.
Cell culture. MDBK cells and MDCK cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) containing 10% fetal bovine serum and 1% penicillin and streptomycin, and
incubated at 37°C with 5% CO2.
Immunization and challenge of mice
6—week old BALB/c (NCI) or JhD (Taconic) mice were immunized with a single dose of 106
plaque forming unit (PFU) of PIV5, PIV5-H7 (for dose response, 104 or 105 PFU were also
used), or PIV5-NP intranasally. Mice were intramuscularly injected with 256 HA units (HAU)
of β-propiolactone-inactivated H7N9 as a control. The mice were then challenged with 10
times the 50% lethal doses (LD50) of A/Anhui/1/2013 (H7N9) and monitored for weight loss
and survival. For the IgA/IgG study, mice were boosted with the same dose at 3 weeks
after immunization.
Immunization and challenge of guinea pigs
Guinea pigs about 3-weeks old were immunized IN with a single 107 PFU dose of PIV5,
PIV5-H7, or 5x106 PFU each of PIV5-H7 plus PIV5-NP. Guinea pigs were intramuscularly in-
jected with 512 HAU of inactivated H7N9 as a control. At 3 weeks after immunization, guinea
pigs were challenged with 100 ID50 of A/Anhui/1/13 (H7N9) via IN and at 1 dpi, naïve guinea
pigs were co-housed with the infected guinea pigs at 1 to 1 (total 48 guinea pigs in 24 cages).
Nasal washes were obtained from guinea pigs at day 2, 4, 6 and 8 after challenge.
Hemagglutination inhibition assay
HAI titers were determined following established WHO protocol (http://www.who.int/
influenza/gisrs_laboratory/manual_diagnosis_surveillance_influenza/en/). Serum samples
from mice or guinea pigs were treated with receptor-destroying enzyme (RDE) to remove non-
specific inhibitors before use. 4 HAU of inactivated H7N9 was mixed with serially-diluted
serum samples for 30 min, followed by the addition of turkey RBCs. After 30 min. samples
were observed for the presence of hemagglutination.
Passive antibody transfer
Guinea pigs about 3-weeks old were immunized IN with a single 107 PFU dose of PIV5-H5 or
PIV5-H7. At 21 days post immunization, sera were obtained and pooled. HAI titers of sera
were determined as before. 100 μl of anti-H7 serum (80 HAI units total) mixed with 100 μl of
PBS was injected intraperitoneally (IP) into BALB/c mice and the mice were challenged next
day with 10 LD50 A/Anhui/1/13 (H7N9) as described above. Similarly, anti-H5 serum contain-
ing 10, 5 or 2.5 HAI units in PBS and 200 μl of PBS were injected into BALB/c mice and the
mice were challenged next day with 10 LD50 A/Vietnam/1203/04 (H5N1). Mortality and mor-
bidity of the mice were monitored.
ELISA
96-well plates were coated with Beta-propiolactone (BPL)-inactivated H7N9 and incubated at
4°C overnight. Plates were then washed with KPL wash solution (KPL, Inc.), and the wells were
blocked with 200 μl KPL wash solution with 5% nonfat dry milk and 0.5% BSA (blocking buff-
er) for 1 h at room temperature. Serial dilutions of serum, nasal wash or bronchoalveolar lavage
PIV5-Based H7N9 Vaccine
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(BAL) samples from PBS-, PIV5-, PIV5-H7-, and i-H7N9-inoculated mice were added to coat-
ed plates and incubated for 1 h. 100 μl goat anti-mouse IgG or IgA conjugated to alkaline phos-
phatase (KPL, Inc.) in blocking buffer was added, and incubated for 1 h at room temperature.
Plates were developed by adding 100 μl pNPP phosphatase substrate (KPL, Inc.), and the reac-
tion was allowed to develop at room temperature. The optical density (OD) at 405 nm was
measured on a Bio-Tek Powerwave XS plate reader.
Statistical analysis
Influenza virus titers were compared using two-tailed MannWhitney test or a Kruskal-Wallis
test followed by Dunn’s multiple comparison to compare groups. Differences in weight loss on
individual days were compared using two-tailed MannWhitney test or a two-way ANOVA fol-
lowed by Bonferroni post-test to compare groups. Guinea pig serum antibody titers were com-
pared by Kruskal-Wallis Test followed by Dunn’s multiple comparison. Differences in survival
were determined by log-rank analysis followed by Bonferroni multiple comparison. All statisti-
cal analysis was done using GraphPad Prism Software (Version 5.04). P values 0.05 were
considered significant.
Animal Use
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was ap-
proved by the University of Georgia Institutional Animal Care and Use Committee (IACUC;
approvals A2011 06–001 and A2014 04–025). Animals were monitored twice daily after influ-
enza virus challenge and scored for clinical symptoms. Animals meeting criteria for euthanasia
(<25% weight loss compared to weight on day of challenge), were humanely euthanized fol-
lowing IACUC-approved methods. Briefly, mice were given an anesthetic overdose (2%
2,2,2-Tribromoethanol, delivered IP) rendering animals dead or completely non-responsive
followed by cervical dislocation. All surviving animals were humanely euthanized at the end of
the study.
Results
PIV5-H7 protects mice against H7N9 challenge
We obtained a codon-optimized HA gene of H7N9 (H7) (A/Anhui/1/2013) and inserted the
gene between the SH and HN genes of PIV5 (Fig. 1). The recovery of PIV5-H7 was confirmed
by RT-PCR and sequencing. In tissue culture, expression of H7 in infected cells was confirmed
by immunofluorescence and PIV5-H7 grew to a titer that was lower (about 1 log) than wild
type PIV5 (Fig. 1). To determine the efficacy of PIV5-H7 in mice, we immunized with a single
dose of 106 plaque-forming units (PFU) of PIV5-H7, PIV5, or PBS via the intranasal route
(IN). Previously, we generated a PIV5 expressing NP of H5N1 (PIV5-NP) and demonstrated
protection in mice against a lethal H1N1 as well as H5N1 challenge [15]. To test whether
PIV5-NP was protective against H7N9, we also immunized mice with 106 PFU of PIV5-NP in-
tranasally. While we intended to use 10 LD50 of A/Anhui/1/13 H7N9, the actual dose was lower
since not all mice in the PBS group died. One mouse survived and re-gained weight (Fig. 2A).
Immunization with PIV5-H7 resulted in 100% survival against challenge with A/Anhui/1/13
H7N9 (Fig. 2A) despite observed weight-loss in the immunized mice (Fig. 2B). Survival was sig-
nificantly different in PIV5-H7 immunized mice compared to either PBS or PIV5 control
groups (P<0.05, log-rank with followed by Bonferroni post-test) Immunization with PIV5-NP
resulted in 60% survival. Interestingly, we also observed a non-specific but nonetheless
PIV5-Based H7N9 Vaccine
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Fig 1. Generation and analysis of PIV5 expressing HA of H7N9 (PIV5-H7). (A) Schematic of PIV5-H7. The PIV5 genome contains seven known
transcriptional units and transcribes eight known viral mRNAs. The V and P mRNAs both originate from the same V/P gene by a RNA editing process called
pseudo-templated transcription. Leader and trailer sequences are important for viral RNA synthesis and transcription initiation. (B) Expression of H7 in
PIV5-H7-infected cells. MDBK cells were mock infected or infected with PIV5-H7. At 2 dpi, the cells were fixed and stained with anti-PIV5-V/P or anti-H7N9
serum. (C) Growth of PIV5-H7. MDBK cells were infected with PIV5 or PIV5-H7 at a moi of 0.1. The media were collected at the indicated intervals and
plaque assays were performed on BHK cells.
doi:10.1371/journal.pone.0120355.g001
PIV5-Based H7N9 Vaccine
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detectable protection afforded by PIV5 inoculation alone. To further determine the efficacy of
PIV5-H7 in mice in comparison to inactivated H7N9, we immunized mice with a single dose of
106, 105, or 104 PFU of PIV5-H7, or PBS via the IN route. Also included was a group immu-
nized with 256 hemagglutination units (HAUs) of inactivated A/Anhui/1/13 (iH7N9), delivered
intramuscularly (IM). It should be noted that this dose is equivalent to 10 times the amount of
inactivated influenza virus normally used as a control [16]. As observed previously, immuniza-
tion with PIV5-H7 protected against lethal challenge with A/Anhui/1/13 H7N9 (Fig. 3A). Also
observed were varying degrees of weight-loss depending on the vaccine dose received (Fig. 3B).
At a dose of 106 PFU, the PIV5-H7 group had the least amount of weight loss (less than 10%
and significantly different from the PBS control on days 2–8 (P<0.05; ANOVA; Fig. 3B). In
contrast, weight loss in iH7N9-vaccinated groups was only significantly different on days 2 and
8 (‡P<0.05; ANOVA). At a dose of 105 PFU, the PIV5-H7 group did better than the inactivated
H7N9 group with significant differences in weight loss on days 2, 6, and 8 (†P<0.05; ANOVA),
compared to PBS controls. Only at a dose of 104 PFU did the PIV5-H7 group not have signifi-
cantly improved weight loss compared to the PBS control group, however 100% of the mice re-
covered, surviving lethal challenge (Fig. 3A). A subset of mice were euthanized three days post
challenge to determine the amount of virus present in the lungs. Despite substantial viral titers
in all groups, mice vaccinated with PIV5-H7 at the 106 PFU dose exhibited significantly lower
titers compared to PBS treated mice (P<0.05, Kruskal-Wallis), supporting the dose dependence
of the vaccine (Fig. 3C). To better understand the mechanism of protection, we primed mice
with 106 PFU of PIV5-H7 or PIV5 or PBS via the IN route or 256 HAUs of iH7N9 delivered IM
and boosted with the same dose and route of immunization at 3 weeks post-prime. At 2 weeks
after boost, we collected sera, nasal washes and BAL washes. We did not detect any H7-specific
IgA or IgG in nasal or BAL washes of PIV5-H7-immunized mice (Fig. 4). The lack of antibodies
for H7 in mice is consistent with existing reports of poor immunogenicity of H7 antigens [6, 7].
This is also consistent with the observation that there is only a moderate reduction in the virus
titers in lungs of immunized mice (Fig. 3C).
Antibody is not required for protection by PIV5-H7
The lack of detectable anti-H7 antibody suggested that anti-H7 did not play a role in protec-
tion. However, it is also possible that our assay was not sensitive enough. To determine whether
antibody is required for PIV5-H7-mediated protection, we immunized JhD mice, which lack
functional antibody [18, 19], and challenged with H7N9. JhD mice were protected by PIV5-H7
Fig 2. PIV5-H7 and PIV5-NP protectedmice against H7N9 challenge. BALB/c mice in groups of 9–10 were infected IN with PIV5-H7 at a dose of 106 PFU,
106 PFU of PIV5-NP, 106 PFU of PIV5, or PBS. Mice were rested for 8 weeks and were then challenged with 10 50% lethal doses (LD50) of A/Anhui/1/2013
(H7N9) and monitored for (A) survival and (B) weight loss. (*P<0.05, log-Rank, compared to PBS or PIV5)
doi:10.1371/journal.pone.0120355.g002
PIV5-Based H7N9 Vaccine
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while inactivated H7N9 did not protect JhD mice against lethal challenge, demonstrating that
antibody was not required for PIV5-H7-mediated protection (Fig. 5). Survival of PIV5-H7 and
PIV5-H7 + PIV5-NP vaccinate mice was significantly better than PBS or iH7N9 groups
(Fig. 5A; P<0.05, log-rank), as was differences in weight loss on days 4, 6, and 8 post-infection
(P<0.05, ANOVA). The results show that cell-mediated immunity played a critical in protec-
tion provided by a PIV5-based H7 influenza vaccine. Consistent with the expected protection
mechanism for inactivated H7N9 vaccines i.e. induction of neutralizing serum antibody re-
sponses, vaccination with inactivated H7N9 did not protect JhD mice from H7N9 challenge.
PIV5-H7 and PIV5-NP protect guinea pigs against H7N9 infection and
transmission
We also investigated whether PIV5-H7 could block infection or subsequent transmission of
H7N9 in guinea pigs, which have been used as a model to study transmission of influenza virus
[20–22]. Guinea pigs were immunized intranasally with PIV5-H7 and sera were collected for
HAI determination. Surprisingly, PIV5-H7 generated high HAI titers in sera, (Fig. 6G; P<0.05
Kruskal-Wallis test). This was likely due to differences between immune systems of mice and
guinea pigs. Interestingly, no HAI titer was detected in guinea pigs after IM injection with 512
HAUs of inactivated H7N9. Guinea pigs were inoculated with 10 ID50 of A/Anhui/1/13 and
one day later, naïve guinea pigs were co-housed with infected animals to assess transmission
(contact animals). Infection of guinea pigs with A/Anhui/1/13 H7N9 does not lead to mortality
Fig 3. Dose response of PIV5-H7. BALB/c mice in groups of 15 were infected IN with PIV5-H7 at a dose of
104, 105 and 106 PFU, or PBS or intramuscularly injected with 256 HAU of iH7N9. Mice were rested for 3
weeks then challenged with 10 LD50 of A/Anhui/1/2013 (H7N9) and monitored for (A) survival and (B) weight
loss. (P<0.05, ANOVA, *compared to PBS on days 2–8; †compared to PBS on days 2, 6, and 8; ‡compared
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[21]. All guinea pigs were monitored for signs of disease and virus shedding. While PIV5-H7
reduced the frequency of infection along with overall titers of H7N9 (Fig. 6F, Day 2; P<0.05,
Kruskal-Wallis test) in the nasal washes guinea pigs, inactivated H7N9 had no effect on infec-
tion rate (100% infected). Virus infection in PIV5-H7-immunized groups also cleared slightly
earlier compared to the PIV5 control group. Considering the results in mice (protection from
virus challenge despite the lack of detection of H7N9-specific antibodies), we hypothesized
that cellular immune responses were critical for the protection. To enhance the cellular im-
mune responses following vaccination, we immunized guinea pigs with a combination of
PIV5-H7 and PIV5-NP. Very excitingly, this vaccination yielded better results than immuniza-
tion with PIV5-H7 alone; it protected 5 out of 6 (83%) guinea pigs from H7N9 infection and
the one that was infected exhibiting a 3 log reduction in virus titer. Moreover, the PIV5-H7
and PIV5-NP combination blocked transmission 100% (Fig. 6). Thus, we have developed a
PIV5-based H7N9 vaccine candidate (containing both PIV5-H7 and PIV5-NP) that was effica-
cious in protecting mice and guinea pigs against H7N9 challenge and reducing transmission to
naïve individuals.
Anti-H7 does not protect mice against H7N9 challenge
Our results demonstrated that for PIV5-based H7N9 vaccine, antibody was not necessary to af-
ford protection in mice. To determine whether anti-H7 was sufficient, we pooled sera from
PIV5-H7 immunized guinea pigs and injected these sera into naïve mice and challenged the
mice with lethal dose of H7N9. As a control, we also injected anti-H5 sera into naïve mice and
challenged the mice with H5N1. Anti-H5 serum given at lower HAI titers provided significant
protection from lethal challenge at 1:8 and 1:16 dilutions (Fig. 7D; P<0.05, log-rank). All of the
mice given anti-H7 serum succumbed to H7N9 challenge (Fig. 7A and B), although there was a
Fig 4. Antibody responses in immunized mice. 96-well plates were coated with inactivated H7N9 and incubated overnight. After blocking, serial dilutions
of serum, nasal wash or bronchoalveolar lavage (BAL) samples were added to the coated plates. After wash, alkaline phosphatase-labeled goat anti-mouse
IgG (A-C) or IgA (D, E) were added and plates were developed using phosphatase substrates. Optical density (OD) was measured at 405 nm on a Bio-Tek
Powerwave XS plate reader.
doi:10.1371/journal.pone.0120355.g004
PIV5-Based H7N9 Vaccine
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slight, but significant improvement in weight loss (Day 6 post-challenge; P<0.05, Mann-Whit-
ney) and survival in anti-H7 serum treated mice (P = 0.032, log-rank), indicating that anti-H7
antibody at the same HAI of anti-H5 was not sufficient to protect against lethal challenge. Fur-
thermore, anti-H7 antibody did not reduce titers of H7N9 in the lungs of immunized and chal-
lenged mice (Fig. 7C).
Discussion
It is interesting that inactivated H7N9, even at 10 times of normal amount, did not generate de-
tectable HAI titer in mice (Fig. 4), yet it was protective of mice against lethal H7N9 challenge.
It is possible that antibodies against other viral proteins such as NA and/or NP are protective.
Fig 5. PIV5-H7 protected JhDmice against H7N9 challenge. JhDmice in a group of 6–7 were infected IN
with PIV5-H7 at a dose of 106 PFU or PBS or intramuscularly injected with 256 HAU of inactivated H7N9.
Mice were rested for 3 weeks, challenged with 10 50% lethal doses (LD50) of A/Anhui/1/2013 (H7N9), and
monitored for (A) survival and (B) weight loss.
doi:10.1371/journal.pone.0120355.g005
PIV5-Based H7N9 Vaccine
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Fig 6. Protection of guinea pigs against H7N9 challenge. (A) Scheme of immunization and infection. Guinea pigs were immunized IN with PIV5 or
PIV5-H7 (107 PFU), or PIV5-H7 + PIV5-NP (5x106 PFU of each). Six guinea pigs were immunized IM with 512 HAUs of iH7N9. At 21 days post immunization
(dpi), guinea pigs were bled and HAI titers were measured. The guinea pigs were then infected IN with 10 ID50 of A/Anhui/1/13 (H7N9). One dpi, one naïve
guinea pig was co-housed with each infected guinea pig in a single cage. Nasal washes were obtained from guinea pigs at day 2, 4, 6 and 8 after challenge
(day post-challenge). Titers of H7N9 in nasal washes were determined by TCID50 assay. (B—E) Nasal wash titers of individual animals. (F) Mean nasal wash
titers (+ SEM). (*P<0.05 compared to PIV5-vaccinated; Kruskal-Wallis test) (G) Hemagglutination inhibition titers of individual vaccinated animals.
(*P< 0.05; Kruskal-Wallis test) Order and shading of bars matches individual guinea pigs for panels B—E, Symbols match for panels F and G.
doi:10.1371/journal.pone.0120355.g006
PIV5-Based H7N9 Vaccine
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Consistent with this theory, inactivated H7N9 did not protect against lethal H7N9 challenge in
JhD mice, which lack antibody. It has been reported before that antibody targeting NA or NP
can be protective [23–30], likely through an antibody-dependent cell-mediated cytotoxicity
(ADCC) or complement-dependent cytotoxicity. The result that high titers of H7N9 were de-
tected in the lungs of inactivated H7N9-vaccinated mice after challenge is consistent with the
non-neutralizing nature of the protection afforded by ADCC or complement-dependent cyto-
toxicity. It is not clear whether these potential mechanisms will make a difference in other ani-
mal models. In the case of guinea pigs, immunization with inactivated H7N9 did not have an
impact on infection. It is not known whether it has an impact on disease progression since the
guinea pig does not have symptoms after H7N9 infection [21].
The majority of current approaches for developing a H7N9 vaccine focus on obtaining HAI
titers higher than 40, the benchmark for an effective influenza vaccine. Our results that anti-
H5 at a dilution of 1:32 had better protection than anti-H7 at 1:1 dilution when both sera had
the same starting HAI titer suggest that anti-H7 was not effective for protection against H7N9
in mice. This raises the question on current practice in using HAI titer ALONE as the bench-
mark for vaccine efficacy and licensure for H7N9 vaccine. A HAI titer of 40 for H5N1 may be
protective, a HAI of 40 for H7N9 may not be. More studies using different animal models will
be needed to further examine this observation.
PIV5 has been used as a live viral vector for vaccine development. Tests of efficacy of PIV5-
based vaccines for influenza viruses, rabies virus and respiratory syncytial virus have been
Fig 7. Protection of anti-H7 serum antibodies. Sera from PIV5-H5 or PIV5-H7 immunized guinea pigs were pooled and assayed for HAI titers. 200 μl of
anti-H7 (HAI titer of 80) diluted 1:2 or naïve serum was injected IP into naïve mice and the mice were challenged at 1 day post-injection with 10 LD50 of H7N9.
200 μl of anti-H5 serum (HAI titer of 80) serially diluted, 1:8, 1:16, and 1:32 was injected IP into mice and the mice were challenged with 10 LD50 of H5N1 the
next day. (A) Mortality of H7N9 challenge after antibody transfer. (B) Weight loss after H7N9 challenge. (C) Virus titers in the lungs of mice at 3 days after
H7N9 challenge. (D) Mortality of H5N1 challenge after antibody transfer.
doi:10.1371/journal.pone.0120355.g007
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performed in mice [11–16, 31, 32]. This is the first time that efficacy of PIV5-based vaccine has
been tested in guinea pigs. Interestingly, PIV5 generated better antibody responses in guinea
pigs than in mice: anti-H7 antibody was detected in guinea pigs but not in mice. The mouse is
not an ideal model for PIV5 infection, as PIV5 does not infect mice well, likely due to the in-
ability of the V protein of PIV5 to block interferon signaling pathway in mouse cells [33]. This
work is encouraging to the field of developing PIV5-based vaccines, especially when immune
responses generated PIV5-based vaccine are not very robust in mice, a common and relatively
inexpensive animal model that has often been used as the first model to test. For many patho-
gens, such asMycobacterium tuberculosis, where guinea pigs are effective infection model, a
PIV5-based vaccine may prove to be effective.
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